Stockreport

ContraFect Announces U.S. FDA Grants Breakthrough Therapy Designation to Exebacase for the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia, Including Right-Sided...

ContraFect Corporation  (CFRX) 
Last contrafect corporation earnings: 3/18 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.contrafect.com
PDF YONKERS, N.Y., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development [Read more]